TABLE 6.

Factors associated with a negative cell IGRA response after vaccination in KT recipients

	Univariate			Multivariate
	OR	95% CI	p-value	OR	95% CI	p-value
Sociodemographics
Age (years)	0.98	0.95–1.023	.49
Sex (ref: female)	0.63	0.26–1.50	.10
Body mass index (kg/m2)	0.99	0.92–1.06	.83
Seasonal vaccine (ref: no)	1.02	0.40–2.57	.96
Darbepoetin treatment (ref: no)	0.46	0.11–1.921	.29
Vitamin D supplementation (ref: no)	0.92	0.32–2.62	.88
Comorbidities
Hypertension	0.84	0.05–14.04	.90
Diabetes mellitus	0.98	0.41–2.32	.96
Cardiovascular disease	0.55	0.22–1.38	.20
Pulmonary disease	2.16	0.75–6.26	.15
Underlying diabetic nephropathy	3.11	0.74–12.94	.11
Blood tests
White blood cells (×103 U/µl)	0.91	0.77–1.088	.32
T lymphocytes (×103 U/µl)	0.56	0.34–0.93	.02	.58	0.35–0.97	.04
C-reactive protein (mg/dl)	1.29	0.80–2.09	.29
Albumin (g/dl)	0.56	0.20–1.54	.26
Transplantation characteristics
Time after transplantation (months)a	0.99	0.99–1.002	.20
Transplantation >1 yeara	0.35	0.13–0.93	.035	.58	0.14–1.05	.06
Transplantation >6 monthsa	0.50	0.16–1.56	.23
Serum creatinine (mg/dl)b	1.02	0.56–1.84	.93
eGFR (ml/min per 1.73 m2)b	0.99	0.97–1.01	.54
Immunosuppression treatment
Prednisone	2.78	0.52–14.62	.22
Mycophenolic acid	1.61	0.26–1.43	.26
Tacrolimus or cyclosporin Ac	—	—	—
Everolimus	1.40	0.52–3.75	.50
Everolimus dose (mg/kg/day)	0.01	0.01–6.34	.83
Everolimus blood levels (ng/ml)	1.71	0.32–1.55	.39

Bold values indicate statistically significant p values (p < .05).

Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; OD, odds ratio; RRT, renal replacement therapy.

^aDifferent multivariate models maintain the three different variables within the model, marginal significance with KT of more than a year.

^bNot significant either including serum creatinine or eGFR.

^cImpossible to calculate, as patients negative without tacrolimus or cyclosporine were = 0.